TJP3

Across TCGA pan-cancer cohorts, TJP3 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated TJP3 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TJP3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TJP3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, UCEC, and COAD are the cancer types where TJP3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.509	0.306	<.001	97	view →
UCEC	DFS	Tertile	All	1.000	0.781	<.001	26	view →
COAD	DFS	Quartile	III,IV	1.000	0.799	.035	24	view →
CCRCC	DFS	Median	All	0.823	0.636	.012	9	view →
LUAD	OS	Tertile	III,IV	0.738	0.270	.025	6	view →
HNSC	DFS	Median	II,III,IV	0.904	0.966	.029	5	view →
GBM	DFS	Quartile	All	0.753	0.214	.024	3	view →
LSCC	DFS	Median	II,III,IV	0.867	0.963	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

TJP3–PDAC (DFS)

Open the PDAC breakdown →